Steatosis is an accumulation of triglicerids within the liver cells and may lead to steatohepatitis. Phospholipidosis is a disruption of the phospholipidases activity, either by direct inhibition or through drug-phospholipid complexes that cannot be broken by them, leading to intracellular phospholipid accumulation. Although not a toxic event by itself, phospholipidosis predict drug and metabolite accumulation that may provoke toxicity within the liver or kidney for example. Drug induced steatosis and/or phospholipidosis can be quantified in the same experiment by High Content Screening.
To learn more on these assays, see also our posters presented in different congress:
In this assay, different well known steatosis and/or phospholipidosis inducers have been tested on HepG2 cells during a 48h period:
Rifampicin did not have any steatosis nor phospholipidosis effect. Cyclosporin A induced only steatosis, whereas Sertraline induced only phospholipidosis. Amiodarone and ketoconazole produced both phospholipidosis and steatosis. These effects are well correlated with effects described in the literature.